Arginase 1 mediates increased blood pressure and contributes to vascular endothelial dysfunction in deoxycorticosterone acetate-salt hypertension

Frontiers in Immunology

Volumn 4, Issue JUL, 2013, Pages

  Toque, Haroldo A ^a   Nunes, Kenia P ^a   Rojas, Modesto ^a   Bhatta, Anil ^a   Yao, Lin ^a   Xu, Zhimin ^a   Romero, Maritza J ^a   Webb, R Clinton ^a   Caldwell, Ruth B ^a   Caldwell, R William ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Arginase; DOCA salt; Endothelial dysfunction; Fibrosis; Hypertension

Indexed keywords

ACETYLCHOLINE; ARGINASE 1; NITROPRUSSIDE SODIUM; PHENYLEPHRINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD VESSEL REACTIVITY; BODY WEIGHT; CONTROLLED STUDY; DEOXYCORTICOSTERONE-SALT INDUCED HYPERTENSION; ENDOTHELIAL DYSFUNCTION; FIBROSIS; GENOTYPE; KNOCKOUT GENE; MESENTERIC ARTERY; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE; UNINEPHRECTOMY; VASODILATATION; WESTERN BLOTTING;

EID: 84883690434     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00219     Document Type: Article

References (36)

1. Lee DE, Cooper RS. Recommendations for global hypertension monitoring and prevention. Curr Hypertens Rep (2009) 11(6):444-9. doi:10.1007/s11906-009-0075-9
2. Bagnost T, Ma L, da Silva RF, Rezakhaniha R, Houdayer C, Stergiopulos N, et al. Cardiovascular effects of arginase inhibition in spontaneously hypertensive rats with fully developed hypertension. Cardiovasc Res (2010) 87(3):569-77. doi:10.1093/cvr/cvq081
3. Shatanawi A, Romero MJ, Iddings JA, Chandra S, Umapathy NS, Verin AD, et al. Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway. Am J Physiol Cell Physiol (2011) 300(5):C1181-92. doi:10.1152/ajpcell.00328.2010
4. Jenkinson CP, Grody WW, Cederbaum SD. Comparative properties of arginases. Comp Biochem Physiol B Biochem Mol Biol (1996) 114(1):107-32. doi:10.1016/0305-0491(95)02138-8
5. Bachetti T, Comini L, Curello S, Bastianon D, Palmieri M, Bresciani G, et al. Coexpression and modulation of neuronal and endothelial nitric oxide synthase in human endothelial cells. J Mol Cell Cardiol (2004) 37(5):939-45. doi:10.1016/j.yjmcc.2004.07.006
6. Ming XF, Barandier C, Viswambharan H, Kwak BR, Mach F, Mazzolai L, et al. Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation (2004) 110(24):3708-14. doi:10.1161/01.CIR.0000142867.26182.32
7. Morris SM Jr. Recent advances in arginine metabolism: roles and regulation of the arginases. Br J Pharmacol (2009) 157(6):922-30. doi:10.1111/j.1476-5381.2009.00278.x
8. Ryoo S, Gupta G, Benjo A, Lim HK, Camara A, Sikka G, et al. Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ Res (2008) 102 (8):923-32. doi:10.1161/CIRCRESAHA.107.169573
9. Berkowitz DE, White R, Li D, Minhas KM, Cernetich A, Kim S, et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation (2003) 108(16):2000-6. doi:10.1161/01.CIR.0000092948.04444.C7
10. Romero MJ, Platt DH, Tawfik HE, Labazi M, El-Remessy AB, Bartoli M, et al. Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res (2008) 102(1):9-102. doi:10.1161/CIRCRESAHA.107.155028
11. Toque HA, Tostes RC, Yao L, Xu Z, Webb RC, Caldwell RB, et al. Arginase II deletion increases corpora cavernosa relaxation in diabetic mice. J Sex Med (2011) 8 (3):722-33. doi:10.1111/j.1743-6109.2010.02098.x
12. Xu W, Kaneko FT, Zheng S, Comhair SA, Janocha AJ, Goggans T, et al. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J (2004) 18(14):1746-8.
13. Zhang C, Hein TW, Wang W, Miller MW, Fossum TW, McDonald MM, et al. Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension (2004) 44(6):93-43. doi:10.1161/01.HYP.0000146907.82869.f2
14. Demougeot C, Prigent-Tessier A, Marie C, Berthelot A. Arginase inhibition reduces endothelial dysfunction and blood pressure rising in spontaneously hypertensive rats. J Hypertens (2005) 23(5):971-8. doi:10.1097/01.hjh.0000166837.78559.93
15. Rodriguez S, Richert L, Berthelot A. Increased arginase activity in aorta of mineralocorticoid-salt hypertensive rats. Clin Exp Hypertens (2000) 22(1):7-85. doi:10.1081/CEH-100100063
16. Johnson FK, Johnson RA, Peyton KJ, Durante W. Arginase inhibition restores arteriolar endothelial function in Dahl rats with salt-induced hypertension. Am J Physiol Regul Integr Comp Physiol (2005) 288(4):R1057-62. doi:10.1152/ajpregu.00758.2004
17. Hein TW, Zhang C, Wang W, Chang CI, Thengchaisri N, Kuo L. Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase. FASEB J (2003) 17(15):2328-30.
18. Iyer RK, Yoo PK, Kern RM, Rozengurt N, Tsoa R, O'Brien WE, et al. Mouse model for human arginase deficiency. Mol Cell Biol (2002) 22(13):4491-8. doi:10.1128/MCB.22.13.4491-4498.2002
19. Toque HA, Romero MJ, Tostes RC, Shatanawi A, Chandra S, Carneiro ZN, et al. Mitogen-activated protein kinase (MAPK) increases arginase activity and contributes to endothelial dysfunction in corpora cavernosa from angiotensin-II-treated mice. J Sex Med (2010) 7(12):3857-67. doi:10.1111/j.1743-6109.2010.01996.x
20. Huynh NN, Andrews KL, Head GA, Khong SM, Mayorov DN, Murphy AJ, et al. Arginase II knockout mouse displays a hypertensive phenotype despite a decreased vasoconstrictory profile. Hypertension (2009) 54(2):322-8. doi:10.1161/HYPERTENSIONAHA.108.121731
21. Somers MJ, Mavromatis K, Galis ZS, Harrison DG. Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation (2000) 101:1722-8. doi:10.1161/01.CIR.101.14.1722
22. Korshunov VA, Daul M, Massett MP, Berk BC. Axl mediates vascular remodeling induced by deoxycorticosterone acetate-salt hypertension. Hypertension (2007) 50(6):1057-62. doi:10.1161/HYPERTENSIONAHA.107.096289
23. Johns C, Gavras I, Handy DE, Salomao A, Gavras H. Models of experimental hypertension in mice. Hypertension (1996) 28(6):1064-9. doi:10.1161/01.HYP.28.6.1064
24. Hartner A, Cordasic N, Klanke B, Veelken R, Hilgers KF. Strain differences in the development of hypertension and glomerular lesions induced by deoxycorticosterone acetate salt in mice. Nephrol Dial Transplant (2003) 18(10):1999-2004. doi:10.1093/ndt/gfg299
25. Weinberger MH, Miller JZ, Luft FC, Grim CE, Fineberg NS. Definitions and characteristics of sodium sensitivity and blood pressure resistance. Hypertension (1986) 8:II127-34.
26. Durante W, Johnson FK, Johnson RA. Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol (2007) 34(9):906-11. doi:10.1111/j.1440-1681.2007.04638.x
27. Demougeot C, Prigent-Tessier A, Bagnost T, Andre C, Guillaume Y, Bouhaddi M, et al. Time course of vascular arginase expression and activity in spontaneously hypertensive rats. Life Sci (2007) 80(12):1128-34. doi:10.1016/j.lfs.2006.12.003
28. Morris SM Jr. Regulation of enzymes of the urea cycle and arginine metabolism. Annu Rev Nutr (2002) 22:87-105. doi:10.1146/annurev.nutr.22.110801.140547
29. Durante W, Liao L, Reyna SV, Peyton KJ, Schafer AI. Transforming growth factor-beta (1) stimulates L-arginine transport and metabolism in vascular smooth muscle cells: role in polyamine and collagen synthesis. Circulation (2001) 103(8):1121-7. doi:10.1161/01.CIR.103.8.1121
30. Li H, Meininger CJ, Hawker JR Jr, Haynes TE, Kepka-Lenhart D, Mistry SK, et al. Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab (2001) 280(1):E7-82.
31. Steppan J, Barodka V, Berkowitz DE, Nyhan D. Vascular stiffness and increased pulse pressure in the aging cardiovascular system. Cardiol Res Pract (2011) 2011:263585. doi:10.4061/2011/263585
32. Beswick RA, Dorrance AM, Leite R, Webb RC. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension (2001) 38(5):1107-11. doi:10.1161/hy1101.093423
33. Sankaralingam S, Xu H, Davidge ST. Arginase contributes to endothelial cell oxidative stress in response to plasma from women with preeclampsia. Cardiovasc Res (2010) 85(1):194-203. doi:10.1093/cvr/cvp277
34. Chandra S, Romero MJ, Shatanawi A, Alkilany AM, Caldwell RB, Caldwell RW. Oxidative species increase arginase activity in endothelial cells through the RhoA/Rho kinase pathway. Br J Pharmacol (2012) 165(2):506-19. doi:10.1111/j.1476-5381.2011.01584.x
35. Matthiesen S, Lindemann D, Warnken M, Juergens UR, Racke K. Inhibition of NADPH oxidase by apocynin inhibits lipopolysaccharide (LPS) induced upregulation of arginase in rat alveolar macrophages. Eur J Pharmacol (2008) 579(1-3):403-10. doi:10.1016/j.ejphar.2007.10.043
36. Zhang W, Baban B, Rojas M, Tofigh S, Virmani SK, Patel C, et al. Arginase activity mediates retinal inflammation in endotoxin-induced uveitis. Am J Pathol (2009) 175(2):891-902. doi:10.2353/ajpath.2009.081115